How Sustained-Release Pellets Work: IR, SR-4 and SR-8 Explained

Release profile is not simply another word for coating. In a functional pellet system, measured release behaviour reflects the interaction between pellet architecture, the release-control layer, active loading, particle properties, processing conditions and the dissolution method used to test the product.

For formulators comparing immediate-release (IR), SR-4 and SR-8 pellet modules, the useful question is therefore not only “how many hours?” It is:

What does the full release specification look like, under what test conditions, and will that profile remain consistent after the pellets are blended and processed into the final dosage form?

This article explains the formulation logic behind functional pellets and uses the current NexaGens caffeine pellet specifications as a practical example. The terms SR-4 and SR-8 are NexaGens product-family designations; they should not be treated as universal regulatory categories.

1. What are functional pellets?

Pellets are small multiparticulate units that can carry an active ingredient and, when required, a functional coating or matrix. In modified-release systems, the active dose is divided across many individual units rather than being contained in one monolithic tablet or capsule.

Pharmaceutical literature on multiparticulate systems is useful for understanding the formulation principles: coated pellets can be engineered to provide different release behaviours, can be combined into multi-unit systems, and can be filled into capsules or incorporated into other dosage forms. The exact construction varies by product, so the term “pellet” does not by itself tell a formulator how the active will be released.^[1,2]

From a B2B ingredient-selection perspective, a functional pellet should therefore be evaluated as a defined material with its own:

• active assay or loading;
• particle-size distribution;
• bulk and tapped density;
• coating or matrix characteristics;
• release / dissolution specification;
• mechanical robustness; and
• application and processing limits.

2. Immediate release vs sustained release

An immediate-release pellet is designed to release the active relatively quickly under its defined dissolution conditions. A sustained-release pellet is designed to slow that release over a longer test period.

The distinction sounds simple, but a serious technical comparison needs more than a label such as “4-hour” or “8-hour.” A release profile is a set of measured values over time. Two products can reach the same final endpoint while behaving very differently during the first one, two or four hours.

That is why multiple time points matter. A specification such as “not less than 85% at 8 hours” does not describe what happened at hour 1, hour 2 or hour 4. Those intermediate points are essential if the release curve itself is part of the formulation design.

It is also important not to turn an in-vitro dissolution period into a consumer or physiological claim. An 8-hour dissolution specification describes the laboratory release test. By itself, it does not establish an 8-hour physiological effect, pharmacokinetic profile or health benefit.

3. IR, SR-4 and SR-8: what changes?

The current NexaGens modified-release platform uses three caffeine pellet modules with different active loadings and release specifications. The values below are current confirmed specification values published by NexaGens.^[4]

For the current platform, the dissolution method is stated as Ph. Eur. 2.9.3 on the NexaGens modified-release page. A buyer comparing data from different suppliers should still request the full product-specific method because apparatus, medium, volume, pH, rotation speed and temperature can materially affect the measured result.

4. How a functional coating changes release

In many coated multiparticulate systems, the functional layer controls how quickly dissolution medium reaches the active and how quickly dissolved material can leave the pellet. The precise mechanism depends on the coating chemistry, coating thickness, porosity, active properties and surrounding medium.^[1,2]

This is why “coated” and “sustained release” are not interchangeable terms. A coating can also be used for protection, taste management or handling without intentionally slowing release. A sustained-release claim should be supported by an actual release or dissolution specification.

Coating integrity is also critical. Reviews of coated multiparticulates show that mechanical stress during downstream processing can damage a functional film and alter release behaviour.^[1,3] The correct question is therefore not only whether the pellet passed dissolution before processing, but whether the intended profile survives the process used to make the finished product.

5. Why active loading changes between profiles

Release-control material occupies mass and volume. In the current NexaGens caffeine range, the IR module has the highest active assay, followed by SR-4 and then SR-8: 85%, 70% and 65% w/w respectively.^[4]

This matters directly to formulation calculations. A formulator should not compare equal pellet masses and assume they deliver equal active quantities.

As a simple formulation example, supplying 100 mg of active caffeine would theoretically require approximately:

• 117.6 mg of an 85% w/w pellet;
• 142.9 mg of a 70% w/w pellet; or
• 153.8 mg of a 65% w/w pellet.

Those figures are mass-balance examples only. A real formulation must also account for the final product specification, manufacturing losses, overage policy, applicable legal requirements and the intended market.

6. Why matched pellet populations matter when blending

One advantage of a modular pellet platform is the ability to combine populations with different release characteristics. In principle, a formulation can contain an immediate-release fraction together with one or more sustained-release fractions.

The difficult part is not simply choosing a percentage on paper. Different particulate populations can segregate during blending, transfer and filling when their particle size, shape or density differ significantly. Pellet and tableting literature identifies size and density differences as important variables in multiparticulate processing.^[3]

The current NexaGens platform therefore develops the IR, SR-4 and SR-8 modules around a matched 500–850 µm target particle-size range and matched physical properties.^[4] The design objective is to reduce the physical mismatch between populations when they are combined.

Even with matched populations, the release profile of a finished blend should be measured rather than assumed. A weighted arithmetic combination of individual release curves is not a substitute for blend-specific dissolution data.

7. How to evaluate a sustained-release pellet

For procurement and formulation teams, the following questions are more useful than simply asking whether a pellet is “sustained release.”

1. What is the complete dissolution method?

Request the pharmacopoeial or validated method, apparatus, rotation speed, medium composition, volume, pH and temperature. Release percentages cannot be meaningfully compared without understanding the method used to generate them.

2. Are there multiple release checkpoints?

Look for a profile with meaningful intermediate time points, not only a final endpoint.

3. What is the batch-to-batch variability?

A representative curve is useful for illustration, but qualification should consider the actual specification and the consistency of production batches.

4. What are the pellet size and density characteristics?

These parameters influence flow, blending, segregation risk and capsule-fill behaviour.

5. What is the active assay?

Longer-release modules can have different active loadings. Formulation calculations should be based on active content, not only pellet mass.

6. Has the intended blend been tested?

If IR and SR populations will be combined, evaluate the actual blend for content uniformity and dissolution.

7. Does processing damage the release-control layer?

If the pellets will be compressed, exposed to high shear or subjected to other mechanical stress, post-process dissolution testing is important.

8. What changes after capsule filling or tableting?

Pellets are attractive because they can be handled as multiple small units, but the finished dosage form still matters.

Capsule filling generally avoids the high compression forces involved in tableting. When coated pellets are compressed into tablets, the functional film can crack or deform if the formulation and process are not designed to protect it. Published reviews therefore emphasise coating flexibility, pellet properties, cushioning excipients and post-compression dissolution testing.^[1,3]

For a nutraceutical project, the practical lesson is simple: qualify the ingredient in the process that will actually be used. Pre-processing data are not always enough.

9. A practical selection framework

A formulator can think about IR, SR-4 and SR-8 as modular tools rather than three versions of the same ingredient.

• IR: consider when the formulation requires a predominantly immediate in-vitro release component.
• SR-4: consider when the target profile calls for an intermediate sustained-release component.
• SR-8: consider when the target profile calls for a longer sustained-release component.
• Blended modules: consider when a project requires a composite profile rather than one fixed population.

The final choice should be based on the required release specification, active loading, total fill mass, dosage form, processing route and blend-verified performance — not on the profile name alone.

NexaGens supplies functional pellet modules for professional B2B formulation evaluation. For a project involving a specific target profile, the next step is to review the product specification, dissolution data and intended blend ratio with the technical team before final formulation decisions are made.

10. Frequently asked questions

Are SR-4 and SR-8 standard regulatory terms?

No. In this article they refer to NexaGens product-family designations for defined sustained-release pellet modules. Other suppliers may use different terminology.

Does an 8-hour dissolution profile prove an 8-hour physiological effect?

No. An in-vitro dissolution profile describes release under a defined laboratory method. It does not, by itself, establish a pharmacokinetic profile, physiological duration or finished-product health claim.

Can IR, SR-4 and SR-8 pellets be blended?

They can be considered as independent formulation modules, but the selected ratio should be evaluated as a real blend. Content uniformity, segregation behaviour and blend-specific dissolution should be verified.

Can sustained-release pellets be compressed into tablets?

Potentially, but compression can damage a functional coating. The process should be developed to preserve pellet integrity and the finished dosage form should be re-tested for dissolution.

What documents should a technical buyer request?

At minimum, review the current product specification, batch CoA, dissolution / release data where applicable, particle-size information, stability information and product-specific processing guidance. The exact documentation package should match the intended market and application.

References

1. Al-Hashimi N, Begg N, Alany RG, Hassanin H, Elshaer A. Oral Modified Release Multiple-Unit Particulate Systems: Compressed Pellets, Microparticles and Nanoparticles. Pharmaceutics. 2018;10(4):176. doi:10.3390/pharmaceutics10040176.
2. Kállai-Szabó N, Lengyel M, Farkas D, et al. Review on Starter Pellets: Inert and Functional Cores. Pharmaceutics. 2022;14(6):1299. doi:10.3390/pharmaceutics14061299.
3. Dwibhashyam VSNM, Ratna JV. Key Formulation Variables in Tableting of Coated Pellets. Indian J Pharm Sci. 2008;70(5):555–564. doi:10.4103/0250-474X.45391.
4. NexaGens. Modified Release — IR, SR-4 and SR-8. https://nexagens.com/pages/modified-release
5. NexaGens. Functional Pellet Technology. https://nexagens.com/pages/functional-pellet-technology

Technical note: Pharmaceutical pellet literature is cited here to explain multiparticulate formulation and coating principles. Product classification, permitted claims, dose, labelling and market compliance for a food supplement or other finished product remain product- and jurisdiction-specific.